|Trade names||Fasinex, Egaten, others|
|Main uses||Fascioliasis, paragonimiasis|
|Side effects||Abdominal pain, fever, headache|
|Defined daily dose||not established|
|Typical dose||10 mg/kg|
|Metabolism||Oxidation to sulfone and sulfoxide metabolites|
|Elimination half-life||22–24 hours|
|Excretion||Feces (>95%), urine (2%), milk (<1%)|
|Chemical and physical data|
|Molar mass||359.658 g·mol−1|
|3D model (JSmol)|
|Melting point||175 to 176 °C (347 to 349 °F)|
Triclabendazole, sold under the brand name Egaten among others, is a medication used to treat fascioliasis and paragonimiasis. It is very effective for both conditions. Treatment in hospital may be required. It is taken by mouth with typically one or two doses being required.
Side effects are generally few, but can include abdominal pain and headaches. Biliary colic may occur due to dying worms. While no harms have been found with use during pregnancy, triclabendazole has not been well studied in this population. It is a member of the benzimidazole family of medications for worms.
Triclabendazole was approved for medical use in the United States in 2019. It is on the World Health Organization's List of Essential Medicines. For human use it can also be obtained from the World Health Organization. It is also used in other animals.
Side effects are generally few, but can include abdominal pain and headaches. Biliary colic may occur due to dying worms. While no harms have been found with use during pregnancy, triclabendazole has not been well studied in this population.
It is a member of the benzimidazole family of anthelmintics. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but no carbamate group. Benzimidazoles such as triclabendazole are generally accepted to bind to beta-tubulin therefore preventing the polymerization of microtubules.
Since late 1990s, triclabendazole became available as a generic drug, as patents expired in many countries. Many products were developed then. Among them, Trivantel 15, a 15% triclabendazole suspension, was launched by Agrovet Market Animal Health in the early 2000s. In 2009, the first triclabendazole injectable solution (combined with ivermectin) was developed and launched, also by Agrovet Market Animal Health. The product, Fasiject Plus, a triclabendazole 36% and ivermectin 0.6% solution, is designed to treat infections by Fasciola hepatica (both immature and adult liver flukes), roundworms and ectoparasites, as well.
Fasinex is a brandname for veterinary use while Egaten is a brandname for human use.
- "TRICLABENDAZOLE oral - Essential drugs". medicalguidelines.msf.org. Archived from the original on 26 November 2020. Retrieved 25 August 2020.
- "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 27 June 2020. Retrieved 21 September 2020.
- World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 94, 96. hdl:10665/44053. ISBN 9789241547659.
- Wolfe, M. Michael; Lowe, Robert C. (2014). "Benzimidazoles". Pocket Guide to GastrointestinaI Drugs. John Wiley & Sons. p. PT173. ISBN 9781118481554. Archived from the original on 20 December 2016.
- "Egaten (triclabendazole)" (PDF). FDA. Archived (PDF) from the original on 2 October 2019. Retrieved 18 February 2019.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "Triclabendazole - Drugs.com". www.drugs.com. Archived from the original on 20 December 2016. Retrieved 10 December 2016.
- "Report of the WHO Informal Meeting on use of triclabendazole in fascioliasis control" (PDF). World Health Organization (WHO). 2006. Archived (PDF) from the original on 15 June 2016. Retrieved 10 December 2016.
- "Drug Trials Snapshots: Egaten". U.S. Food and Drug Administration (FDA). 13 February 2019. Archived from the original on 15 December 2019. Retrieved 18 March 2020.